This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for oncology nurses and pharmacists who wish to enhance their knowledge concerning the management of patients with myelodysplastic syndromes (MDS).

Learning Objectives
At the completion of this activity participants should be able to:

• Discuss survival rates for MDS and the impact on patient quality of life
• Evaluate the difficulties associated with the treatment of elderly patients with MDS
• Review results of recent clinical trials of the use of FDA-approved and investigational therapies, including hypomethylating and immunomodulatory agents, for the treatment of MDS

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Manuel Afable, II, RN, BSN has nothing to disclose.

Megan Reiman, PharmD, BCOP has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.